SM
ESPR

SG3 Management’s Esperion Therapeutics ESPR Stock Holding History

SG3 Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-17,500
Closed -$898K – 936
2020
Q2 		$898K Buy
17,500
+2,500
+17% +$105K 0.06% 304
2020
Q1 		$473K Buy
+15,000
New +$792K 0.06% 174

Other funds holding ESPR

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return

SG3 Management's ESPR Position: Q1 2023 in Review

SG3 Management sold out of Esperion Therapeutics (ESPR) in Q1 2023, closing a stake of 6,000 shares — an estimated $37.4K sold.

SG3 Management first reported a position in ESPR in Q1 2020 and held it in 4 quarters. The position peaked at $378K in Q1 2020. 164 funds tracked by Wall St. Rank hold ESPR as of Q1 2023.

  • SG3 Management reported no remaining Esperion Therapeutics position as of Q1 2023 after selling out during the quarter.
  • SG3 Management sold 6,000 Esperion Therapeutics shares in Q1 2023, an estimated $37.4K.
  • SG3 Management first reported a position in Esperion Therapeutics in Q1 2020 and held it in 4 quarters.
  • SG3 Management's Esperion Therapeutics position peaked at $378K in Q1 2020.
  • 164 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2023.

Based on SG3 Management's 13F filing for Q1 2023, filed 15 May 2023.